Key Points
- EVP Paul Mahon sold 11,000 shares on Nov 26 at an average price of $486.06, totaling $5.35M and reducing his stake by 23.02% to 36,781 shares (≈$17.88M).
- United Therapeutics reported Q3 EPS of $7.16 (above consensus) but slightly missed revenue at $799.5M; the stock trades near its 52‑week high, has a market cap of about $21.0B, and carries a consensus "Moderate Buy" rating with an average target of $505.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 11,000 shares of the business's stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $486.06, for a total value of $5,346,660.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at $17,877,772.86. This trade represents a 23.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
United Therapeutics Price Performance
Shares of UTHR stock opened at $488.43 on Thursday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $492.62. The stock's 50-day moving average is $444.71 and its two-hundred day moving average is $359.64. The firm has a market cap of $21.03 billion, a P/E ratio of 18.51, a PEG ratio of 4.96 and a beta of 0.77.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million during the quarter, compared to analysts' expectations of $812.87 million. During the same quarter in the previous year, the business posted $6.39 EPS. The firm's quarterly revenue was up 6.8% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.
Wall Street Analyst Weigh In
Several analysts have commented on UTHR shares. Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an "outperform" rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of United Therapeutics in a research note on Tuesday. Cantor Fitzgerald increased their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 10th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Finally, HC Wainwright upped their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a "buy" rating in a research note on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $505.00.
Check Out Our Latest Analysis on UTHR
Institutional Trading of United Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. AE Wealth Management LLC acquired a new stake in United Therapeutics in the 1st quarter valued at approximately $248,000. Avantax Advisory Services Inc. boosted its position in shares of United Therapeutics by 226.5% in the first quarter. Avantax Advisory Services Inc. now owns 1,933 shares of the biotechnology company's stock valued at $596,000 after acquiring an additional 1,341 shares during the period. HB Wealth Management LLC grew its stake in shares of United Therapeutics by 12.6% in the first quarter. HB Wealth Management LLC now owns 1,200 shares of the biotechnology company's stock worth $370,000 after acquiring an additional 134 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of United Therapeutics by 44.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,746 shares of the biotechnology company's stock worth $14,410,000 after acquiring an additional 14,282 shares during the last quarter. Finally, LPL Financial LLC increased its position in United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after acquiring an additional 11,007 shares during the period. Institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
